/
AZTR
$0.17+$0.01 (+5.99%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.7M
16M shares
52-week range
$0.10 – $1.83
4% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
197.40%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-986.83
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $110.0K | $284.0K | $686.0K | $7.5M | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $453.1K |
| Gross profit | $110.0K | $284.0K | $686.0K | $7.5M | −$453.1K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $5.4M | $6.1M | $3.6M | $4.72B | $4.84B |
| Operating income | −$9.2M | −$9.5M | −$7.5M | −$10.99B | −$11.0M |
| EBITDA | −$8.8M | −$10.0M | −$10.7M | −$8.5M | −$10.5M |
| Net income | −$8.9M | −$10.7M | −$11.3M | −$9.0M | −$11.0M |
| Net margin | -8127.0% | -3760.7% | -1644.9% | -119.6% | — |
| EPS (diluted) | -3.33 | -3.98 | -4.20 | -0.36 | -2.25 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.26 | $-0.26–$-0.26 | 1 |
| 2027 | $0 | $-0.10 | $-0.10–$-0.10 | 1 |
| 2028 | $20M | $-0.10 | $-0.13–$-0.08 | 2 |
| 2029 | $21M | $-0.06 | $-0.06–$-0.06 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.29
Price
$0.17
Implied upside
+70%
Peer comparison
Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
www.azitrainc.com- Employees
- 13
- IPO / List date
- Jun 16, 2023
- HQ
- BRANFORD, CT
Held by traders on TradeandTell
No one on the platform currently holds AZTR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AZTR as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-21 | 1-for-6.66reverse |
| 2024-07-01 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded AZTR yet.
